Introduction
Covid-19 broke out in 2019 and spread rapidly. Confirmed cases could be found in countries around the world. The novel coronavirus has a raised spike glycoprotein on its surface. The S glycopretein of the virus binds to angiotensin converting enzyme 2 of the recipient cell, which causes the virus to enter the cell. Viruses can also enter cells through membrane fusion and release nucleic acids to synthesize new viruses, causing cytopathic disease and death, thus leading to tissue and organ lesions. Novel Coronavirus is mainly related to pulmonary infection, which can involve multiple organs such as liver, spleen, cardiovascular and cerebrovascular systems, stomach and esophagus, etc. In serious cases, it can develop into acute respiratory distress syndrome, metabolic acidosis and multi-organ dysfunction syndrome, or even death. The initial clinical symptoms are mostly fever, dry cough and fatigue. A few patients are accompanied by nasal congestion, runny nose, pharyngeal pain, myalgia and diarrhea, some patients may have no obvious symptoms. Previous studies[1] suggest that the most prevalent comorbidities were hypertension(17%),DM (8%) and CVD (5%) in COVID-19. It is important to evaluate patients’ clinical symptoms based on current influencing factors and comorbidities. Therefore, it is necessary to evaluate possible factors that may result the progression or improvement of COVID-19 patients. Therefore, the influencing factors of status for COVID-19 patients and the result was investigated and analyzed in order to provide guidance about the treatment of this disease.